Available exclusively from CONMED through MTF Biologics, MOPSTM preservation and storage services create osteochondral allografts with consistently high viable chondrocyte density.1
- Higher Viable Chondrocyte Density1
In an initial clinical comparison study, allografts preserved using MOPS™ maintained 98.8% viable chondrocyte density at 40 to 55 days of storage, compared to standard of care (SOC) allografts, which maintained only 22.9% viable chondrocyte density at 21 to 28 days after recovery. Importantly, all MOPS-preserved allografts evaluated in the study had higher than the desired minimum essential viability level of 70%, while only 27% of SOC allografts evaluated exceeded the desired viability level at the time of implantation.
MOPS-preserved allografts averaged 98.8% viable chondrocyte density at 40 to 55 days1 – giving surgeons and their patients significantly more time to schedule the surgery. Meanwhile, studies show that mean chondrocyte viability in osteochondral allografts stored using the standard tissue bank protocols was below the minimum essential level by 28 days from the time of recovery.1, 4
- Lower Revision Rates 1, 3, 4
MOPS-preserved allografts are consistently associated with significantly lower revision and failure rates compared to SOC preserved allografts in the first 4 years after transplantation.1, 3, 4 The consistently high chondrocyte viability in MOPS-preserved grafts at the time of transplantation is considered to be a major factor contributing to these more successful outcomes.
MTF Biologics never uses H2O2, harmful chemicals, or terminal radiation during allograft processing – instead choosing to minimally process donor tissue to help preserve the allograft’s natural biomechanical and healing properties.5
Due to the nature of this very desirable tissue and limited availability, MTF Biologics offers graft matching services specifically designed to provide orthopedic surgeons with the best possible anatomically matched allografts to meet each individual patient’s unique needs.
1Stoker et al. “Chondrocyte Viability at Time of Transplantation for Osteochondral Allografts Preserved by the Missouri Osteochondral Preservation System versus Standard Tissue Bank Protocol.” Journal of Knee Surgery. Volume 31, Issue 8, pp. 772-780, September 2018.
2 Cook et al. “Importance of Donor Chondrocyte Viability for Osteochondral Allografts.” The American Journal of Sports Medicine. Vol 44, Issue 5, pp. 1260 – 1268. February 26, 2016.
3 Rucinski et al. “Effects of Compliance With Procedure-Specific Postoperative Rehabilitation Protocols on Initial Outcomes After Osteochondral and Meniscal Allograft Transplantation in the Knee”. The Orthopaedic Journal of Sports Medicine, Volume 7, Issue 11. November 2019.
4 Stannard, James P., and James L. Cook. “Prospective Assessment of Outcomes After Primary Unipolar, Multisurface, and Bipolar Osteochondral Allograft Transplantations in the Knee: A Comparison of 2 Preservation Methods.” The American Journal of Sports Medicine, Mar. 2020.
5Maletis GB, Inacio MC, Funahashi TT. Risk factors associated with revision and contralateral anterior cruciate ligament reconstructions in the Kaiser Permanente ACLR registry. Am J Sports Med. 2015 Mar;43(3):641-7.